REBECCA O'BRYAN: Open Payments
NPI 1972096337 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,146 in 59 payments from 11 companies in 2025. Trend: 2023 $973 · 2024 $1,173 · 2025 $1,146
Food & beverage: $1,146
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $410 |
| Novo Nordisk Inc | 11 | $201 |
| Astellas Pharma US Inc | 7 | $134 |
| Lilly USA, LLC | 7 | $113 |
| PFIZER INC. | 5 | $83 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $67 |
| Exact Sciences Corporation | 3 | $49 |
| MILLICENT US INC | 2 | $36 |
| Boston Scientific Corporation | 1 | $20 |
| Organon LLC | 1 | $19 |
Products named: VRAYLAR, UBRELVY, Veozah, Wegovy, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA.
Industry payments across IN — which companies pay providers there.
